{"id":"W4388047700","doi":"10.1136/jitc-2023-sitc2023.0609","title":"609 Phase 1/2a dose selection of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced solid malignancies","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Antibody; Pharmacokinetics; In vitro; Monoclonal antibody; Pharmacology; Receptor; Cancer research; Cell cycle; Medicine; Chemistry; Internal medicine; Immunology; Cancer; Biochemistry","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000337211,0.0002531847,0.0005097082,0.0003818156,0.00007217557,0.00002437755,0.00007563802,0.00014876,0.00001340185],"category_scores_gemma":[0.000151454,0.0002140729,0.00007443111,0.0009261249,0.0002712912,0.0002321253,0.00002399944,0.0001940137,0.000004833104],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001075022,"about_ca_system_score_gemma":0.0002702431,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002953772,"about_ca_topic_score_gemma":0.0002830194,"domain_scores_codex":[0.9982277,0.00003789812,0.0005402478,0.0003863497,0.0003840174,0.0004238072],"domain_scores_gemma":[0.9991868,0.0000440414,0.0002130929,0.0002310025,0.0001118363,0.0002132338],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0034489,0.0007530731,0.779337,0.0006532394,0.0001518987,0.0001367917,0.0008728281,0.0003482468,0.2102766,0.00002781777,0.0006276034,0.003365943],"study_design_scores_gemma":[0.01273101,0.0009513926,0.9315233,0.001061657,0.00004767562,0.00002120028,0.0001498223,0.0002712385,0.05135383,0.00003883393,0.001601342,0.0002487519],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9981677,0.0002855644,0.000003390594,0.0005066362,0.0001742337,0.000627418,0.00002817462,0.00007280106,0.0001341],"genre_scores_gemma":[0.9989185,0.0003692206,0.0001865893,0.0001473065,0.00003773478,0.00002391881,0.0001208833,0.00003678243,0.000159028],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1589228,"threshold_uncertainty_score":0.8729641,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0101685356109609,"score_gpt":0.2704615126143873,"score_spread":0.2602929770034264,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}